OPICAPONE AS FIRST-LINE ADJUNCTIVE LEVODOPA TREATMENT IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS: BIPARK-I AND II COMBINED POST-HOC ANALYSIS

被引:0
|
作者
Ferreira, J. J. [1 ]
Poewe, W. [2 ]
Antonini, A. [3 ]
Gama, H. [4 ]
Rocha, J. F. [4 ]
Magalhaes, D. [4 ,5 ]
Soares-da-Silva, P. [5 ,6 ,7 ]
机构
[1] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Lisbon, Portugal
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Univ Padua, Dept Neurosci, Padua, Italy
[4] BIAL Portela & Ca SA, Med Affairs Dept, Coronado, Portugal
[5] Univ Porto, Porto, Portugal
[6] BIAL Portela & Ca SA, Dept Res & Dev, Coronado, Portugal
[7] Univ Porto, MedInUP Ctr Drug Discovery & Innovat Med, Porto, Portugal
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A 214
引用
收藏
页码:E63 / E63
页数:1
相关论文
共 50 条
  • [31] Influence of demographic characteristics in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
    Santos, A.
    Ferreira, J.
    Lees, A.
    Reichmann, H.
    Poewe, W.
    Ikedo, F.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2019, 34 : S81 - S81
  • [32] Influence of demographic characteristics in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
    Santos, A.
    Ferreira, J.
    Lees, A.
    Reichmann, H.
    Poewe, W.
    Ikedo, F.
    Magalhaes, D.
    Rocha, J.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 841 - 841
  • [33] Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
    Lees, A.
    Ferreira, J.
    Rascol, O.
    Poewe, W.
    Stocchi, F.
    Santos, A.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2019, 34 : S57 - S57
  • [34] Influence of baseline off-time in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II
    Santos, A.
    Ferreira, J.
    Lees, A.
    Reichmann, H.
    Poewe, W.
    Ikedo, F.
    Magalhaes, D.
    Rocha, F.
    Soares-da-Silva, P.
    Savic, N.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [35] Influence of baseline OFF-time in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
    Santos, A.
    Ferreira, J.
    Lees, A.
    Reichmann, H.
    Poewe, W.
    Ikedo, F.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2019, 34 : S81 - S81
  • [36] Early morning dystonia in Parkinson's patients receiving opicapone versus entacapone: a Post-Hoc Analysis of BIPARK-I
    Stocchi, F.
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Antonini, A.
    Rocha, J. F.
    MOVEMENT DISORDERS, 2022, 37 : S356 - S356
  • [37] Early Morning Dystonia in Parkinson's Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I
    Stocchi, F.
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Antonini, A.
    Rocha, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 446 - 446
  • [38] Efficacy of opicapone in Parkinson's disease patients with 'early' motor fluctuations: The BIPARK-I double-blind experience
    Kulisevsky, J.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Gama, H.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S106 - S106
  • [39] Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data
    Rocha, F.
    Poewe, W.
    Rascol, O.
    Lees, A.
    Ferreira, J.
    Santos, A.
    Magalhaes, D.
    Soares-da-Silva, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [40] OPICAPONE'S ADDED BENEFIT AS A FIRST-LINE ADJUNCTIVE THERAPY TO LEVODOPA AND WHEN USED PROMPTLY FOR MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE
    Ebersbach, G.
    Ferreira, J. J.
    Antonini, A.
    Santos, A.
    Magalhaes, D.
    Rocha, J. -F.
    Soares-da-Silva, P.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E71 - E72